170 related articles for article (PubMed ID: 34465822)
21. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
22. OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer.
Weixler B; Cremonesi E; Sorge R; Muraro MG; Delko T; Nebiker CA; Däster S; Governa V; Amicarella F; Soysal SD; Kettelhack C; von Holzen UW; Eppenberger-Castori S; Spagnoli GC; Oertli D; Iezzi G; Terracciano L; Tornillo L; Sconocchia G; Droeser RA
Oncotarget; 2015 Nov; 6(35):37588-99. PubMed ID: 26439988
[TBL] [Abstract][Full Text] [Related]
23. Analysis of Spatial Organization of Suppressive Myeloid Cells and Effector T Cells in Colorectal Cancer-A Potential Tool for Discovering Prognostic Biomarkers in Clinical Research.
Zwing N; Failmezger H; Ooi CH; Hibar DP; Cañamero M; Gomes B; Gaire F; Korski K
Front Immunol; 2020; 11():550250. PubMed ID: 33193316
[TBL] [Abstract][Full Text] [Related]
24. Budding and tumor-infiltrating lymphocytes - combination of both parameters predicts survival in colorectal cancer and leads to new prognostic subgroups.
Lang-Schwarz C; Melcher B; Haumaier F; Lang-Schwarz K; Rupprecht T; Vieth M; Sterlacci W
Hum Pathol; 2018 Sep; 79():160-167. PubMed ID: 29787819
[TBL] [Abstract][Full Text] [Related]
25. The prognostic significance of VISTA and CD33-positive myeloid cells in cutaneous melanoma and their relationship with PD-1 expression.
Choi JW; Kim YJ; Yun KA; Won CH; Lee MW; Choi JH; Chang SE; Lee WJ
Sci Rep; 2020 Sep; 10(1):14372. PubMed ID: 32873829
[TBL] [Abstract][Full Text] [Related]
26. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer.
Blando J; Sharma A; Higa MG; Zhao H; Vence L; Yadav SS; Kim J; Sepulveda AM; Sharp M; Maitra A; Wargo J; Tetzlaff M; Broaddus R; Katz MHG; Varadhachary GR; Overman M; Wang H; Yee C; Bernatchez C; Iacobuzio-Donahue C; Basu S; Allison JP; Sharma P
Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1692-1697. PubMed ID: 30635425
[TBL] [Abstract][Full Text] [Related]
27. Dickkopf-related protein 1, a new biomarker for local immune status and poor prognosis among patients with colorectal liver Oligometastases: a retrospective study.
Sui Q; Zheng J; Liu D; Peng J; Ou Q; Tang J; Li Y; Kong L; Jiang W; Xiao B; Chao X; Pan Z; Zhang H; Ding PR
BMC Cancer; 2019 Dec; 19(1):1210. PubMed ID: 31830954
[TBL] [Abstract][Full Text] [Related]
28. Regular Aspirin Use Associates With Lower Risk of Colorectal Cancers With Low Numbers of Tumor-Infiltrating Lymphocytes.
Cao Y; Nishihara R; Qian ZR; Song M; Mima K; Inamura K; Nowak JA; Drew DA; Lochhead P; Nosho K; Morikawa T; Zhang X; Wu K; Wang M; Garrett WS; Giovannucci EL; Fuchs CS; Chan AT; Ogino S
Gastroenterology; 2016 Nov; 151(5):879-892.e4. PubMed ID: 27475305
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of costimulatory molecule B7-H3 expression on CD3(+) T cells in colorectal carcinoma.
Mao Y; Sun J; Wang WP; Zhang XG; Hua D
Chin Med J (Engl); 2013 Aug; 126(16):3035-8. PubMed ID: 23981607
[TBL] [Abstract][Full Text] [Related]
30. Metformin changes the immune microenvironment of colorectal cancer in patients with type 2 diabetes mellitus.
Saito A; Kitayama J; Horie H; Koinuma K; Ohzawa H; Yamaguchi H; Kawahira H; Mimura T; Lefor AK; Sata N
Cancer Sci; 2020 Nov; 111(11):4012-4020. PubMed ID: 32794612
[TBL] [Abstract][Full Text] [Related]
31. Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment.
Park JH; Powell AG; Roxburgh CS; Horgan PG; McMillan DC; Edwards J
Br J Cancer; 2016 Mar; 114(5):562-70. PubMed ID: 26859693
[TBL] [Abstract][Full Text] [Related]
32. VISTA expression and patient selection for immune-based anticancer therapy.
Martin AS; Molloy M; Ugolkov A; von Roemeling RW; Noelle RJ; Lewis LD; Johnson M; Radvanyi L; Martell RE
Front Immunol; 2023; 14():1086102. PubMed ID: 36891296
[TBL] [Abstract][Full Text] [Related]
33. The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.
Hosseinkhani N; Derakhshani A; Shadbad MA; Argentiero A; Racanelli V; Kazemi T; Mokhtarzadeh A; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():676181. PubMed ID: 34093577
[TBL] [Abstract][Full Text] [Related]
34. Tumour immune microenvironment biomarkers predicting cytotoxic chemotherapy efficacy in colorectal cancer.
Wilkinson K; Ng W; Roberts TL; Becker TM; Lim SH; Chua W; Lee CS
J Clin Pathol; 2021 Oct; 74(10):625-634. PubMed ID: 33753562
[TBL] [Abstract][Full Text] [Related]
35. Genetic evidence that intratumoral T-cell proliferation and activation are associated with recurrence and survival in patients with resected colorectal liver metastases.
Maker AV; Ito H; Mo Q; Weisenberg E; Qin LX; Turcotte S; Maithel S; Shia J; Blumgart L; Fong Y; Jarnagin WR; DeMatteo RP; D'Angelica MI
Cancer Immunol Res; 2015 Apr; 3(4):380-8. PubMed ID: 25600439
[TBL] [Abstract][Full Text] [Related]
36. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma.
Mima K; Sukawa Y; Nishihara R; Qian ZR; Yamauchi M; Inamura K; Kim SA; Masuda A; Nowak JA; Nosho K; Kostic AD; Giannakis M; Watanabe H; Bullman S; Milner DA; Harris CC; Giovannucci E; Garraway LA; Freeman GJ; Dranoff G; Chan AT; Garrett WS; Huttenhower C; Fuchs CS; Ogino S
JAMA Oncol; 2015 Aug; 1(5):653-61. PubMed ID: 26181352
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials.
Moretto R; Corallo S; Belfiore A; Rossini D; Boccaccino A; Lonardi S; Centonze G; Morano F; Germani MM; Loupakis F; Morelli L; Urbani L; Brich S; Marmorino F; Prisciandaro M; Aprile G; Fassan M; Cillo U; Cattaneo L; Fontanini G; De Braud F; Falcone A; Milione M; Pietrantonio F; Cremolini C
Eur J Cancer; 2020 Aug; 135():78-88. PubMed ID: 32554314
[TBL] [Abstract][Full Text] [Related]
38. Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer.
Berntsson J; Nodin B; Eberhard J; Micke P; Jirström K
Int J Cancer; 2016 Sep; 139(5):1129-39. PubMed ID: 27074317
[TBL] [Abstract][Full Text] [Related]
39. Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy.
Guo L; Wang C; Qiu X; Pu X; Chang P
Front Immunol; 2020; 11():1052. PubMed ID: 32547556
[TBL] [Abstract][Full Text] [Related]
40. Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer.
Shen Y; Guan Y; Hummel JJ; Shyu CR; Mitchem JB
BMC Cancer; 2020 Feb; 20(1):124. PubMed ID: 32059711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
